Skip to content
Men Under Microscope – Lifestyle
Author:
Ambrosia Biosciences
Ambrosia Biosciences Announces the Nonclinical Data Profiles of Two Oral Small Molecule Programs: A GLP-1 Receptor Agonist Intended for Once-Weekly Dosing and a GIP Receptor Antagonist
November 15, 2026
Ambrosia Biosciences Announces Late-Breaking Poster Presentations at ObesityWeek® 2026
November 10, 2026
Ambrosia Biosciences to Participate in Upcoming Investor Conferences
September 16, 2026
Ambrosia Biosciences Enhances Clinical and Scientific Expertise with Chief Medical Officer and Scientific Advisory Board Appointments
July 28, 2026
Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate
June 5, 2026